Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
FDA expanded EVO/EVO+ age indication, preliminary Q1 sales exceeded $90M with China rebound and Americas growth, Q1 results due 2026-05-13, and shares remain up about 32% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Positive Cash Flow ⢠Elevated Valuation STAA's profitability, cash flow, and liquidity have rebounded sharply, but its high valuation and legacy losses warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Persistent selling ⢠Support test ⢠Oversold rebound Support Level: $20.82; next support $20.00 Resistance Level: $22.40â$22.70 STAA remains in a bearish last-month trend; watch $20.82 support for an oversold bounce, while a break below $20.00 could extend losses and $22.40â$22.70 remains initial resistance.
Sentiment & News
Key News Insights: ⢠Institutional Investment ⢠Leadership Expansion ⢠Market Tailwinds STAAR gains institutional backing and experienced leadership, reinforcing its expansion strategy and lens-based vision correction growth.
AI Summary
STAA's turnaround is real but not yet investable as a durable global growth story: China drove over half of quarterly sales and nearly all the acceleration, so investors should require several quarters of sustained free cash flow, stable working capital, and materially faster ex-China growth before underwriting its premium valuation.
Description
STAAR Surgical Company designs, manufactures and sells implantable intraocular lenses and the delivery systems used to place them, along with preloaded cataract lenses, injector components and related surgical instruments. Its products, which address refractive errors and cataract treatment, are marketed primarily to ophthalmologists and surgical centers through a mix of direct sales forces and distributor networks across North America, Europe and Asia. The company was founded in 1982 and is headquartered in Lake Forest, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | STAA | STAAR Surgical Company | FDA expanded EVO/EVO+ age indication, preliminary Q1 sales exceeded $90M with China rebound and Americas growth, Q1 results due 2026-05-13, and shares remain up about 32% over 21 trading days. | Closed | +5.9% |
| Apr 10 | Apr 17 | STAA | STAAR Surgical Company | STAAR Surgical has a fresh revenue surprise and momentum: preâannounced Q1 net sales above ~$90M drove a ~25% twoâday spike, and FDA expansion of EVO/EVO+ ICL indication (21â60 years) broadens its market. Shares are ~42% above their 21âday mean, with strong volume and activist/institutional buying, making STAA a highâvelocity nearâterm trade around the formal earnings release. | Closed | -5.1% |